Quick Answer
OCULAR THERAPEUTIX, INC reported R&D Expense of $197.10 million for fiscal year 2025.
OCULAR THERAPEUTIX, INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $197.10M | +54.4% |
| 2024 | $127.64M | +109.0% |
| 2023 | $61.05M | +14.2% |
| 2022 | $53.46M | +6.7% |
| 2021 | $50.08M | +74.5% |
| 2020 | $28.69M | -30.2% |
| 2019 | $41.09M | +11.3% |
| 2018 | $36.91M | +19.5% |
| 2017 | $30.88M | +14.1% |
| 2016 | $27.07M | +1.7% |
| 2015 | $26.61M | +40.9% |
| 2014 | $18.88M | +79.5% |
| 2013 | $10.52M | -8.9% |
| 2012 | $11.54M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $52.36M | +41.3% | +2.5% |
| June 30, 2025 | $51.08M | +77.0% | +19.2% |
| March 31, 2025 | $42.86M | +106.7% | +15.7% |
| September 30, 2024 | $37.05M | +146.7% | +28.4% |
| June 30, 2024 | $28.86M | +91.2% | +39.2% |
| March 31, 2024 | $20.73M | +40.6% | +38.1% |
| September 30, 2023 | $15.02M | +9.5% | -0.5% |
| June 30, 2023 | $15.09M | +15.2% | +2.4% |
- OCULAR THERAPEUTIX, INC showed an increase of +54.4% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, OCULAR THERAPEUTIX, INC’s r&d expense has grown by 1607.9% (from $11.54 million to $197.10 million).
- The most recent figure is from OCULAR THERAPEUTIX, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: